Committee for Medicinal Products for Human Use
The Committee for Medicinal Products for Human Use (CHMP) is responsible for providing scientific opinions on all questions concerning medicinal products for human use, in accordance with Regulation N° 726/2004/EC.
The CHMP assesses applications relating to medicinal products for which the centralized procedure applies (Community Marketing Authorization) and arbitrates in cases where there is disagreement between Member States for which the mutual recognition or decentralized procedure applies (marketing authorization procedure involving two or more Member States). The CHMP also acts in referral cases where there are concerns relating to the protection of public health or other Community interests at stake.
The meeting involves the participation of representatives from the National Competent Authorities (NCA’s), including European Economic Area Competent Authorities (Iceland, Norway and Liechtenstein), the European Commission and the European Medicines Agency.
The CHMP holds monthly meetings, except for the month of August, at the premises of the European Medicines Agency, based in London. Informal meetings can be organized by the Member State holding the Presidency of the Council of the European Union.
An informal meeting of the CHMP will be held on 30 September – 01 October (Antwerp) during the Belgian Presidency. Joint meetings with the Committee for Orphan Medicinal Products, the Paediatric Committee, the Committee for Advanced Therapies and the Scientific Advice Working Party are foreseen.